These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 21410458)

  • 1. Characterization of three diaminopyrimidines as potent and selective antagonists of P2X3 and P2X2/3 receptors with in vivo efficacy in a pain model.
    Ballini E; Virginio C; Medhurst SJ; Summerfield SG; Aldegheri L; Buson A; Carignani C; Chen YH; Giacometti A; Lago I; Powell AJ; Jarolimek W
    Br J Pharmacol; 2011 Jul; 163(6):1315-25. PubMed ID: 21410458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications.
    Marucci G; Dal Ben D; Buccioni M; Martí Navia A; Spinaci A; Volpini R; Lambertucci C
    Expert Opin Ther Pat; 2019 Dec; 29(12):943-963. PubMed ID: 31726893
    [No Abstract]   [Full Text] [Related]  

  • 3. Endogenous opioid mechanisms partially mediate P2X3/P2X2/3-related antinociception in rat models of inflammatory and chemogenic pain but not neuropathic pain.
    McGaraughty S; Honore P; Wismer CT; Mikusa J; Zhu CZ; McDonald HA; Bianchi B; Faltynek CR; Jarvis MF
    Br J Pharmacol; 2005 Sep; 146(2):180-8. PubMed ID: 16041397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist.
    Gever JR; Soto R; Henningsen RA; Martin RS; Hackos DH; Panicker S; Rubas W; Oglesby IB; Dillon MP; Milla ME; Burnstock G; Ford AP
    Br J Pharmacol; 2010 Jul; 160(6):1387-98. PubMed ID: 20590629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation.
    Richards D; Gever JR; Ford AP; Fountain SJ
    Br J Pharmacol; 2019 Jul; 176(13):2279-2291. PubMed ID: 30927255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat.
    Jarvis MF; Burgard EC; McGaraughty S; Honore P; Lynch K; Brennan TJ; Subieta A; Van Biesen T; Cartmell J; Bianchi B; Niforatos W; Kage K; Yu H; Mikusa J; Wismer CT; Zhu CZ; Chu K; Lee CH; Stewart AO; Polakowski J; Cox BF; Kowaluk E; Williams M; Sullivan J; Faltynek C
    Proc Natl Acad Sci U S A; 2002 Dec; 99(26):17179-84. PubMed ID: 12482951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of P2X3 and P2X2/3 Receptors by Monoclonal Antibodies.
    Shcherbatko A; Foletti D; Poulsen K; Strop P; Zhu G; Hasa-Moreno A; Melton Witt J; Loo C; Krimm S; Pios A; Yu J; Brown C; Lee JK; Stroud R; Rajpal A; Shelton D
    J Biol Chem; 2016 Jun; 291(23):12254-70. PubMed ID: 27129281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of aurintricarboxylic acid as a potent allosteric antagonist of P2X1 and P2X3 receptors.
    Obrecht AS; Urban N; Schaefer M; Röse A; Kless A; Meents JE; Lampert A; Abdelrahman A; Müller CE; Schmalzing G; Hausmann R
    Neuropharmacology; 2019 Nov; 158():107749. PubMed ID: 31461640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic blockade of P2X3 and P2X2/3 receptors attenuates bone cancer pain behaviour in rats.
    Kaan TK; Yip PK; Patel S; Davies M; Marchand F; Cockayne DA; Nunn PA; Dickenson AH; Ford AP; Zhong Y; Malcangio M; McMahon SB
    Brain; 2010 Sep; 133(9):2549-64. PubMed ID: 20802203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.
    Garceau D; Chauret N
    Pulm Pharmacol Ther; 2019 Jun; 56():56-62. PubMed ID: 30902655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrrolinone derivatives as a new class of P2X3 receptor antagonists Part 2: Discovery of orally bioavailable compounds.
    Tobinaga H; Kameyama T; Asahi K; Horiguchi T; Oohara M; Tada Y; Fuchino K; Jikihara S; Endoh T; Kurihara N; Kanda Y; Ogawa M; Tamura N; Yagi S; Taniguchi E; Takahara Y; Shimada S; Takeyama C; Yamamoto S; Shinohara S; Kai H
    Bioorg Med Chem Lett; 2019 Mar; 29(5):688-693. PubMed ID: 30728111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of temporomandibular joint P2X3 and P2X2/3 receptors in carrageenan-induced inflammatory hyperalgesia in rats.
    Teixeira JM; Oliveira MC; Nociti FH; Clemente-Napimoga JT; Pelegrini-da-Silva A; Parada CA; Tambeli CH
    Eur J Pharmacol; 2010 Oct; 645(1-3):79-85. PubMed ID: 20558155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic administration of the selective P2X3, P2X2/3 receptor antagonist, A-317491, transiently attenuates cancer-induced bone pain in mice.
    Hansen RR; Nasser A; Falk S; Baldvinsson SB; Ohlsson PH; Bahl JM; Jarvis MF; Ding M; Heegaard AM
    Eur J Pharmacol; 2012 Aug; 688(1-3):27-34. PubMed ID: 22634164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dioxotriazine derivatives as a new class of P2X
    Kai H; Horiguchi T; Kameyama T; Asahi K; Endoh T; Jikihara S; Hasegawa T; Tanaka S; Nozu A; Takeyama C; Tomari M; Takahashi F; Tamura N; Yagi S; Itoh T; Isou Y
    Bioorg Med Chem Lett; 2021 Apr; 37():127833. PubMed ID: 33540044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P2X3 and P2X2/3 receptors activation induces articular hyperalgesia by an indirect sensitization of the primary afferent nociceptor in the rats' knee joint.
    Teixeira JM; Parada CA; Tambeli CH
    Eur J Pharmacol; 2020 Jul; 879():173054. PubMed ID: 32145326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flexible subunit stoichiometry of functional human P2X2/3 heteromeric receptors.
    Kowalski M; Hausmann R; Schmid J; Dopychai A; Stephan G; Tang Y; Schmalzing G; Illes P; Rubini P
    Neuropharmacology; 2015 Dec; 99():115-30. PubMed ID: 26184350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Potent Antiallodynic Agents for Neuropathic Pain Targeting P2X3 Receptors.
    Jung YH; Kim YO; Lin H; Cho JH; Park JH; Lee SD; Bae J; Kang KM; Kim YG; Pae AN; Ko H; Park CS; Yoon MH; Kim YC
    ACS Chem Neurosci; 2017 Jul; 8(7):1465-1478. PubMed ID: 28323403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P2X3 and P2X2/3 Receptors Play a Crucial Role in Articular Hyperalgesia Development Through Inflammatory Mechanisms in the Knee Joint Experimental Synovitis.
    Teixeira JM; Bobinski F; Parada CA; Sluka KA; Tambeli CH
    Mol Neurobiol; 2017 Oct; 54(8):6174-6186. PubMed ID: 27709491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical application of a P2X2/P2X3 purine receptor inhibitor suppresses the bitter taste of medicines and other taste qualities.
    Flammer LJ; Ellis H; Rivers N; Caronia L; Ghidewon MY; Christensen CM; Jiang P; Breslin PAS; Tordoff MG
    Br J Pharmacol; 2024 Sep; 181(17):3282-3299. PubMed ID: 38745397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spontaneous firing and evoked responses of spinal nociceptive neurons are attenuated by blockade of P2X3 and P2X2/3 receptors in inflamed rats.
    Xu J; Chu KL; Brederson JD; Jarvis MF; McGaraughty S
    J Neurosci Res; 2012 Aug; 90(8):1597-606. PubMed ID: 22422599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.